Paper Review Records
All Paper Review Records
10 valid samples · Newest publication first
Review days = acceptance date − received date. PDF, DOI, and publisher-page sources are retained.
Safety and tolerability of topical mesenchymal stromal cell secretome in persistent corneal epithelial disease—a phase 1b clinical trial
AuthorsFarshad Abedi; Jeonghyun (Esther) Kwon; Iskra Araujo; Zarife J. Yucel; Rebecca Jung; Mohammad Soleimani; Seungwon An; Mahmood Ghassemi; Khandeker N Anwar; Zohreh Arabpour; Monazzah A. Sarwar; Elmer Y. Tu; Peiman Hematti; Charlotte E. Joslin; Nadim Mahmud; Ali R. Djalilian
AffiliationsDepartment of Ophthalmology and Visual Sciences, Illinois Eye and Ear Infirmary, University of Illinois, Chicago, Illinois, USA; Division of Hematology/Oncology, Department of Medicine, University of Illinois College of Medicine, Chicago, Illinois, USA; Department of Pharmacy Practice, Retzky College of Pharmacy, University of Illinois, Chicago, Illinois, USA; Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin, USA; Division of Epidemiology and Biostatistics, University of Illinois at Chicago
Sequential CD2/CD3/CD28 activation improves nonviral large-payload chimeric antigen receptor knock-in at the T cell receptor α constant locus
AuthorsWei Wen; Xiang Li; Tong Liu; Shu-Man Zhang; Di Sun; Xi-Die Zhao; Chong-Yan Cheng; Li-Ming Zhang; Jian-Ping Zhang; Xiao-Bing Zhang
AffiliationsState Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China; Tianjin Institutes of Health Science, Tianjin, China
Haploidentical transplantation versus umbilical cord blood transplantation in acute myeloid leukemia with measurable residual disease
AuthorsMasahiro Teramoto; Yoshimitsu Shimomura; Masamitsu Yanada; Shohei Mizuno; Koji Nagafuji; Hirohisa Nakamae; Masao Ogata; Noboru Asada; Tetsuya Eto; Toshihiko Ando; Atsushi Wake; Masatsugu Tanaka; Masashi Sawa; Naoyuki Uchida; Yuta Hasegawa; Masahito Tokunaga; Hideki Nakasone; Fumihiko Ishimaru; Junya Kanda; Yoshiko Atsuta; Takaaki Konuma
AffiliationsDepartment of Hematology, Hyogo Medical University Hospital, Nishinomiya, Japan; Department of Hematology, Kobe City Hospital Organization Kobe City Medical Center General Hospital, Kobe, Japan; Division of Environmental Medicine and Population Sciences, Department of Social Medicine, Graduate School of Medicine, Osaka University, Suita, Japan; Department of Hematology and Oncology, Nagoya City University East Medical Center, Nagoya, Japan; Division of Hematology, Department of Internal Medicine, Aichi Medical University School of Medicine, Nagakute, Japan; Division of Hematology and Oncology, Department of Medicine, Kurume University Hospital, Kurume, Japan; Department of Hematology, Osaka Metropolitan University Hospital, Osaka, Japan; Department of Medical Oncology and Hematology, Oita University Faculty of Medicine, Yufu, Japan; Department of Hematology, Okayama University Hospital, Okayama, Japan; Department of Hematology, Hamanomachi Hospital, Fukuoka, Japan; Division of Hematology, Respiratory Medicine and Oncology, Department of Internal Medicine, Faculty of Medicine, Saga University, Saga, Japan; Department of Hematology, Federation of National Public Service Personnel Mutual Aid Associations, Toranomon Hospital Kajigaya, Kawasaki, Japan; Department of Hematology, Kanagawa Cancer Center, Kanagawa, Japan; Department of Hematology and Oncology, Anjo Kosei Hospital, Anjo, Japan; Department of Hematology, Federation of National Public Service Personnel Mutual Aid Associations, Toranomon Hospital, Tokyo, Japan; Department of Hematology, Hokkaido University Hospital, Sapporo, Japan; Department of Hematology, Imamura General Hospital, Kagoshima, Japan; Division of Emerging Medicine for Integrated Therapeutics (EMIT), Center for Molecular Medicine, Jichi Medical University, Shimotsuke, Japan; Division of Hematology, Jichi Medical University Saitama Medical Center, Saitama, Japan; Japanese Red Cross Blood Service Headquarters, Tokyo, Japan; Department of Hematology, Graduate School of Medicine, Kyoto University, Kyoto, Japan; Japanese Data Center for Hematopoietic Cell Transplantation, Nagakute, Japan; Department of Registry Science for Transplant and Cellular Therapy, Aichi Medical University School of Medicine, Nagakute, Japan; Department of Hematology/Oncology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan
Multicenter validation study on post-thaw viability testing of cryopreserved hematopoietic progenitor cell products
AuthorsWanxing Cui; Cheryl Cox; Kevin Land; Serey-Phorn Sea; Qingdong Guan; Anginett Batista; Yuki Cui; Angeline Giftakis; Nasreen Haroon; Brett Keefe; Kumar Karyampudi; Darryl Miciano; Rachel Murillo; Melba Marie Page; Marie Tulloch; Federico Rodriguez; Ronit Reich-Slotky; Nadim Mahmud; Joseph Schwartz
AffiliationsCell Therapy Manufacturing Facility, MedStar Georgetown University Hospital, Washington, DC, USA; H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, USA; Vitalant Cellular Therapy Lab, Tempe, Arizona, USA; CHU de Québec–Université Laval, Québec City, Québec, Canada; Health Sciences Centre, Winnipeg, Manitoba, Canada; Orlando Health Cancer Institute, Orlando, Florida, USA; Georgetown University School of Medicine, Washington, DC, USA; Hackensack University Medical Center, Hackensack, New Jersey, USA; University of Illinois Hospital and Health Sciences System (UI Health), Chicago, Illinois, USA; Foundation for the Accreditation of Cellular Therapy, Omaha, Nebraska, USA
Human mesenchymal stromal cell extracellular vesicles maintain therapeutic miRNA cargo despite exposure to cystic fibrosis bronchoalveolar lavage fluid
AuthorsSara Rolandsson Enes; Thomas H. Hampton; Jayita Barua; Zeta Mui; Tobias Tertel; Bernd Giebel; David H. McKenna; Pingzhao Hu; Alix Ashare; Bruce A. Stanton; Claudia C. Dos Santos; Daniel J. Weiss
AffiliationsDepartment of Medicine, Larner College of Medicine, University of Vermont, Burlington, Vermont, USA; Department of Experimental Medical Science, Lund University, Lund, Sweden; Department of Microbiology and Immunology, Geisel School of Medicine at Dartmouth, Hanover, New Hampshire, USA; Department of Medicine and the Keenan Center for Biomedical Research, Interdepartmental Division of Critical Care, St. Michael's Hospital, University of Toronto, Toronto, Ontario, Canada; Institute of Transfusion Medicine, University Hospital Essen, University of Duisburg-Essen, Essen Germany; Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, Minnesota, USA; Dept of Biochemistry, Western University, London, Ontario, Canada; Section of Pulmonary and Critical Care Medicine, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, USA
Overcoming access barriers in European CAR-T therapy: the role of decentralized manufacturing and the EASYGEN framework
AuthorsDominik Griebling; Anna Rebecca Scheiwe; Ralf Kuhlen; Chloé Zech; Pia Müller; Christian Rische; Vivian Längst; Chris Wegener; Lexie Schmidt; Paige Bothwell; Kyle Thompson; Katrin Mestermann; Carmen Sanges; David Krones; Mirko Müller; Anna Dünkel; Michael Hudecek; Ulrike Köhl; Ayal Hendel; Dmitry Kashanin; Vivienne Williams; Julia Schüler; Natacha Bolaños; Louise McNamara; Tuula Rintala; Anna Sureda; Afschin Gandjour; Theresa D. Ahrens; Patrick Mennig; Eduard Christiaan Groen; Bertram Glass; Agnes Vosen; Julia Busch-Casler; Marija Radic; Anika Teichert; Ralf Hoffmann; Thomas Brzoska; Catrina Pietralla; Jens O. Brunner; Theresa Kagerbauer; Christin Zündorf; George S. Baillie; Nattaporn Phanthaphol; Felipe Prósper; Juan R. Rodriguez Madoz; Cristina Carames; Sonja Steppan
AffiliationsFresenius SE & Co. KGaA, Bad Homburg, Germany; Fresenius Kabi, Lake Zurich, Illinois 60047, USA; Fraunhofer Institute for Cell Therapy and Immunology IZI, Leipzig, Germany; Institute of Nanotechnology and Advanced Materials, The Mina and Everard Goodman Faculty of Life Sciences, Bar-Ilan University, Safed, Israel; Cellix Limited, Dublin, Ireland; Charles River Laboratories Germany GmbH, Freiburg, Germany; European Society for Blood and Marrow Transplantation, Barcelona, Spain; Frankfurt School of Finance & Management, Germany; Fraunhofer Institute for Experimental Software Engineering IESE, Kaiserslautern, Germany; Helios Hospital Berlin-Buch GmbH, Berlin, Germany; Helmholtz-Zentrum Dresden-Rossendorf (HZDR), Dresden, Germany; Philips Intellectual Property & Standards, Eindhoven, The Netherlands; Pro-Liance Global Solutions GmbH, Münster, Germany; Technical University of Denmark (DTU), Kongens Lyngby, Copenhagen, Denmark; TQ Therapeutics GmbH, Munich, Germany; School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, UK; Hematology and Cell Therapy Department, Clinica Universidad de Navarra, Cancer Center Clinica Universidad de Navarra (CCUN), Centro de Investigacion Biomedica en Red de Cancer (CIBERONC), 31009, Pamplona, Spain; Hemato-Oncology Program, Cima Universidad de Navarra, Cancer Center Clinica Universidad de Navarra (CCUN), Centro de Investigacion Biomedica en Red de Cancer (CIBERONC), IdiSNA, Pamplona, Spain; Quirónsalud Healthcare Network, Madrid, Spain
Automated expansion of iPSCs enables scalable extracellular vesicle production with anti-senescence bioactivity
AuthorsToshihiko Nambara; Tammee M. Parsons; Ana-Caroline Raulin; Angelica Gaona; Bhaskar Roy; Takahisa Kanekiyo
AffiliationsDepartment of Neuroscience, Mayo Clinic, Jacksonville, Florida, USA
Higher yields of Vγ9Vδ2 T cells from peripheral blood than umbilical cord blood via interleukin-12 and interleukin-18
AuthorsShih-Feng Cho; Wan-En Liao; Yi-Chang Liu; Te-Fu Chan; Shian-Ren Lin; Chia-Chun Tu; Ya-Fang Cheng; Chih-Hao Fang; Yuan-Yuan Huang; Shiu-Lan Wang; Wan-Yu Lai; Yee Chao; Li-Tzong Chen; Jan-Mou Lee
AffiliationsDivision of Hematology and Oncology, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, 80738, Taiwan; FullHope Biomedical Co. Ltd., New Taipei City, Taiwan; Department of Gynecology and Obstetrics, Kaohsiung Medical University Hospital, Kaohsiung, 80756, Taiwan; Division of Gastroenterology, Department of Internal Medicine, Kaohsiung Medical University Hospital, and Center for Cancer Research and College of Medicine, Kaohsiung Medical University, Kaohsiung, 80738, Taiwan
Retrospective comparison of mesenchymal stromal cells and antithymocyte globulin as second-line therapy for acute graft-versus-host disease
AuthorsMakoto Murata; Seitaro Terakura; Junya Kanda; Naoyuki Uchida; Satoshi Yoshihara; Takahiro Fukuda; Keisuke Kataoka; Atsushi Wake; Noriko Doki; Shuichi Ota; Maho Sato; Masahito Tokunaga; Yasuo Mori; Hirohisa Nakamae; Moeko Hino; Makoto Onizuka; Ken Tabuchi; Yoshiko Atsuta; Takanori Teshima
AffiliationsDepartment of Hematology, Shiga University of Medical Science, Otsu, Japan; Department of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan; Department of Hematology, Kyoto University, Kyoto, Japan; Department of Hematology, Toranomon Hospital, Tokyo, Japan; Department of Hematology, Hyogo Medical University Hospital, Nishinomiya, Japan; Department of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, Tokyo, Japan; Division of Hematology, Department of Medicine, Keio University School of Medicine, Tokyo, Japan; Division of Molecular Oncology, National Cancer Center Research Institute, Tokyo, Japan; Department of Hematology, Toranomon Hospital, Kajigaya Kawasaki, Tokyo, Japan; Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan; Department of Hematology, Sapporo Hokuyu Hospital, Sapporo, Japan; Department of Hematology/Oncology, Osaka Women’s and Children’s Hospital, Izumi, Japan; Department of Hematology, Imamura General Hospital, Kagoshima, Japan; Hematology, Oncology & Cardiovascular medicine, Kyushu University Hospital, Fukuoka, Japan; Department of Hematology, Osaka Metropolitan University Hospital, Osaka, Japan; Department of Pediatrics, School of Medicine, Chiba University, Chiba, Japan; Department of Hematology/Oncology, Tokai University School of Medicine, Isehara, Japan; Japanese Data Center for Hematopoietic Cell Transplantation, Nagakute, Japan; Department of Registry Science for Transplant and Cellular Therapy, Aichi Medical University School of Medicine, Nagakute, Japan; Department of Hematology, Hokkaido University Faculty of Medicine, Sapporo, Japan
MSC-delivered high-affinity variants of soluble PD1 lead to tumor regression
AuthorsSerap Gokcen; Tianyuan Chu; Phoebe Elizabeth Blair; Natalia Magdalena Krajewska; Greg Nicholas Brooke; Stuart Rushworth; Philippe Pierre Laissue; Ralf Michael Zwacka; Andrea Mohr
AffiliationsSchool of Life Sciences, Protein Structure and Mechanisms of Disease Group, Cancer and Stem Cell Biology Group, University of Essex, Colchester, UK; School of Life Sciences, Protein Structure and Mechanisms of Disease Group, Molecular Oncology Laboratory, University of Essex, Colchester, UK; Metabolic Health Research Centre, Norwich Medical School, University of East Anglia, Norwich, UK; School of Life Sciences, Bioimaging Facility, University of Essex, Colchester, UK
Expert Matching · Case Demo
Turn Your Submission Goalsinto a Verifiable Journal Plan
Share your field, deadline, and author profile. CrushSCI uses real review records to suggest a title direction, shortlist journals, and estimate timelines.
